-+ 0.00%
-+ 0.00%
-+ 0.00%

Ligand Pharmaceuticals to buy XOMA Royalty for USD 39 per share cash

PUBT·04/27/2026 12:17:11
Listen to the news
Ligand Pharmaceuticals to buy XOMA Royalty for USD 39 per share cash
  • Ligand Pharmaceuticals agreed to buy XOMA Royalty for USD 39 per share in cash, valuing equity at about USD 739 million.
  • XOMA Royalty shareholders will also receive one non-transferable contingent value right per share tied to 75% of net proceeds from pending litigation over TREMFYA commercialization.
  • Ligand expects deal to close in Q3 2026.
  • Ligand raised 2026 adjusted EPS guidance to USD 8.5-9.5, lifting revenue outlook to USD 270-310 million.
  • Transaction is expected to be accretive to adjusted EPS, including an estimated USD 1.5 per share lift in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-179085), on April 27, 2026, and is solely responsible for the information contained therein.